Pregabalin Capsule
Product Images NDC 71205-816

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-816). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 (Pregabalin Capsules 1)

An illustration showing the formula for creatinine clearance (CLCr). The formula is the product of (140 minus age in years) and weight in kilograms, divided by 72 times serum creatinine in mg/dL, multiplied by 0.85 for female patients.*

FDA Label Image

Lk (Pregabalin Capsules 10)

A bar chart showing responder rates (%) for three groups: Placebo (22.6% response, 93 subjects), 2.5 mg/kg/day dose (29.1% response, 103 subjects), and 10 mg/kg/day dose (40.6% response, 96 subjects). The vertical axis represents responder rate percentage.*

FDA Label Image

9 (Pregabalin Capsules 11)

A line graph depicting the percent of patients improved against percent improvement in pain from baseline for Pregabalin at doses of 300 mg, 450 mg, and 600 mg daily, compared to a placebo. The graph shows the comparative efficacy trends of different doses of Pregabalin in pain improvement over a range of percent improvements.*

FDA Label Image

10 (Pregabalin Capsules 12)

A line chart comparing the estimated percentage of subjects without LTR (likely loss to retention) over a period of 180 days between Pregabalin and Placebo groups. The x-axis represents days, ranging from 0 to 180, and the y-axis represents the estimated percentage of subjects without LTR, ranging from 0% to 100%. Two lines are shown: a solid line for Pregabalin and a dashed line for Placebo, illustrating different retention rates over time.*

FDA Label Image

11 (Pregabalin Capsules 13)

A line graph comparing the percentage of subjects improved over various levels of percent improvement from baseline to week 12 BOCF. The graph shows two curves representing Pregabalin and Placebo, with Pregabalin's curve generally above the Placebo's, indicating a higher percent of subjects improved at most levels of improvement.*

FDA Label Image

12 (Pregabalin Capsules 14)

A line graph comparing the percent of subjects improved over placebo for Pregabalin versus placebo. The x-axis represents percent improvement from baseline to Week 16 BOCF, ranging from 0 to 100. The y-axis shows the percent of subjects improved, from 0 to 100%. Two curves are plotted: one for Pregabalin showing higher improvement rates and one for placebo with lower rates.*

FDA Label Image

71205-816-60 (Pregabalin Capsules 19)

Pregabalin 75 mg capsules label from Proficient Rx LP. The label indicates 60 capsules per container, with instructions to dispense the Medication Guide. The capsules are white/orange hard gelatin, printed with black ink codes. Manufactured by Amneal Pharmaceuticals Pvt. Ltd., Ahmedabad, India. Includes NDC 71205-816-60 and schedule C-V designation with RX only status.*

FDA Label Image

Df (Pregabalin Capsules 2)

Chemical structure of Pregabalin showing its molecular arrangement with amino and carboxylic acid functional groups.*

FDA Label Image

1 (Pregabalin Capsules 3)

A line graph illustrating the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, showing the relative efficacy over a range of pain improvement percentages.*

FDA Label Image

2 (Pregabalin Capsules 4)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg taken three times a day versus placebo. The vertical axis shows percent of patients improved, and the horizontal axis shows percent improvement in pain, with Pregabalin showing consistently higher improvement than placebo.*

FDA Label Image

3 (Pregabalin Capsules 5)

A line graph showing the percent improvement in pain from baseline versus the percent of patients improved for Pregabalin capsules at different dosages (75 mg, 150 mg, and 300 mg, each taken two times a day) compared to placebo. The curves illustrate higher improvement rates with increasing doses of Pregabalin relative to placebo.*

FDA Label Image

4 (Pregabalin Capsules 6)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows the comparison of pain improvement across these treatment groups over a range of improvement percentages.*

FDA Label Image

5 (Pregabalin Capsules 7)

A line graph comparing percent improvement in pain from baseline on the x-axis with percent of patients improved on the y-axis. It displays three lines representing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing patient response across various pain improvement percentages.*

FDA Label Image

6 (Pregabalin Capsules 8)

Bar chart depicting responder rates (%) across different dosages in two clinical studies (E1 and E3). Study E1 compares placebo and varied Pregabalin dosages (50 mg/day to 600 mg/day) with responder rates increasing up to 51% at 600 mg/day BID. Study E3 compares placebo, 600 mg/day Pregabalin BID, and 600 mg/day TID, with responder rates up to 40%. The x-axis shows dosage groups, and the y-axis shows responder rates percentage.*

FDA Label Image

7 (Pregabalin Capsules 9)

A dose-response line chart showing seizure reduction percentages from baseline versus dose in mg/day for Pregabalin. Four study groups are represented: Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID, each showing increasing seizure reduction with higher doses. Significant p-values are noted near data points, illustrating dose-dependent efficacy.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.